TMED5

Across TCGA pan-cancer cohorts, TMED5 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMED5 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TMED5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMED5 expression acts as an unfavorable survival marker, although some lineages such as LUAD and COAD show a favorable association.

LUAD, HNSC, and COAD are the cancer types where TMED5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.961	0.840	.002	23	view →
HNSC	DFS	Median	All	0.899	0.984	.006	13	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
PDAC	DFS	Tertile	III,IV	0.542	1.000	.016	4	view →
CCRCC	OS	Median	All	0.668	1.000	.013	3	view →
LSCC	DFS	Quartile	All	0.826	0.345	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMED5–LUAD (DFS)

Open the LUAD breakdown →